Ultragenyx Wins Accelerated Approval for Genglycos, First Gene Therapy for GSDIa

Company: Ultragenyx · Event Type: Accelerated Approval · Product: Genglycos (pariglasgene brecaparvovec-opnr; DTX401) · Mechanism: AAV8 Gene Therapy · Indication: Glycogen Storage Disease Type Ia · Announcement Date: August 19, 2026 Summary The FDA granted accelerated approval to Ultragenyx’s Genglycos (pariglasgene brecaparvovec-opnr; DTX401), the first…